Capricor Therapeutics Stock Net Income
| CAPR Stock | USD 21.57 1.95 8.29% |
As of the 29th of January, Capricor Therapeutics shows the Downside Deviation of 6.42, risk adjusted performance of 0.0955, and Mean Deviation of 12.35. Capricor Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Capricor Therapeutics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Capricor Therapeutics is priced correctly, providing market reflects its regular price of 21.57 per share. Given that Capricor Therapeutics has jensen alpha of 4.85, we suggest you to validate Capricor Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.
Capricor Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 107.4028 | Revenue | Earnings Share (1.75) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -36.4 M | -34.6 M | |
| Net Loss | -36.4 M | -34.6 M | |
| Net Loss | -26.1 M | -24.8 M | |
| Net Loss | (1.03) | (1.09) |
Capricor | Net Income | Build AI portfolio with Capricor Stock |
Latest Capricor Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Capricor Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Capricor Therapeutics financial statement analysis. It represents the amount of money remaining after all of Capricor Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Capricor Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Capricor Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (40.47 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Capricor Net Income Regression Statistics
| Arithmetic Mean | (15,907,443) | |
| Geometric Mean | 6,481,850 | |
| Coefficient Of Variation | (82.34) | |
| Mean Deviation | 10,620,161 | |
| Median | (13,657,028) | |
| Standard Deviation | 13,097,958 | |
| Sample Variance | 171.6T | |
| Range | 42.9M | |
| R-Value | (0.86) | |
| Mean Square Error | 48.1T | |
| R-Squared | 0.74 | |
| Significance | 0.00001 | |
| Slope | (2,226,580) | |
| Total Sum of Squares | 2744.9T |
Capricor Net Income History
Other Fundumenentals of Capricor Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Capricor Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Capricor Therapeutics is extremely important. It helps to project a fair market value of Capricor Stock properly, considering its historical fundamentals such as Net Income. Since Capricor Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Capricor Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Capricor Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Capricor have expansion opportunities? Factors like these will boost the valuation of Capricor Therapeutics. Projected growth potential of Capricor fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Capricor Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (1.75) | Revenue Per Share | Quarterly Revenue Growth (0.08) | Return On Assets | Return On Equity |
The market value of Capricor Therapeutics is measured differently than its book value, which is the value of Capricor that is recorded on the company's balance sheet. Investors also form their own opinion of Capricor Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Capricor Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Capricor Therapeutics' market value can be influenced by many factors that don't directly affect Capricor Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Capricor Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Capricor Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Capricor Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Capricor Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Capricor Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Capricor Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Capricor Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Capricor Therapeutics or generate 0.0% return on investment in Capricor Therapeutics over 90 days. Capricor Therapeutics is related to or competes with Cabaletta Bio, Lexeo Therapeutics, ProQR Therapeutics, Entrada Therapeutics, Immutep, Allogene Therapeutics, and Editas Medicine. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell a... More
Capricor Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Capricor Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Capricor Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.42 | |||
| Information Ratio | 0.1149 | |||
| Maximum Drawdown | 386.29 | |||
| Value At Risk | (10.26) | |||
| Potential Upside | 11.97 |
Capricor Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Capricor Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Capricor Therapeutics' standard deviation. In reality, there are many statistical measures that can use Capricor Therapeutics historical prices to predict the future Capricor Therapeutics' volatility.| Risk Adjusted Performance | 0.0955 | |||
| Jensen Alpha | 4.85 | |||
| Total Risk Alpha | 1.29 | |||
| Sortino Ratio | 0.8263 | |||
| Treynor Ratio | 0.6724 |
Capricor Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0955 | |||
| Market Risk Adjusted Performance | 0.6824 | |||
| Mean Deviation | 12.35 | |||
| Semi Deviation | 4.43 | |||
| Downside Deviation | 6.42 | |||
| Coefficient Of Variation | 858.25 | |||
| Standard Deviation | 46.14 | |||
| Variance | 2128.76 | |||
| Information Ratio | 0.1149 | |||
| Jensen Alpha | 4.85 | |||
| Total Risk Alpha | 1.29 | |||
| Sortino Ratio | 0.8263 | |||
| Treynor Ratio | 0.6724 | |||
| Maximum Drawdown | 386.29 | |||
| Value At Risk | (10.26) | |||
| Potential Upside | 11.97 | |||
| Downside Variance | 41.15 | |||
| Semi Variance | 19.62 | |||
| Expected Short fall | (16.08) | |||
| Skewness | 7.89 | |||
| Kurtosis | 63.45 |
Capricor Therapeutics Backtested Returns
Capricor Therapeutics is dangerous given 3 months investment horizon. Capricor Therapeutics secures Sharpe Ratio (or Efficiency) of 0.12, which signifies that the company had a 0.12 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-seven different technical indicators, which can help you to evaluate if expected returns of 5.79% are justified by taking the suggested risk. Use Capricor Therapeutics Downside Deviation of 6.42, mean deviation of 12.35, and Risk Adjusted Performance of 0.0955 to evaluate company specific risk that cannot be diversified away. Capricor Therapeutics holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 7.98, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Capricor Therapeutics will likely underperform. Use Capricor Therapeutics treynor ratio, as well as the relationship between the semi variance and day median price , to analyze future returns on Capricor Therapeutics.
Auto-correlation | -0.65 |
Very good reverse predictability
Capricor Therapeutics has very good reverse predictability. Overlapping area represents the amount of predictability between Capricor Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Capricor Therapeutics price movement. The serial correlation of -0.65 indicates that roughly 65.0% of current Capricor Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.65 | |
| Spearman Rank Test | -0.28 | |
| Residual Average | 0.0 | |
| Price Variance | 5.68 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Capricor Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Capricor Therapeutics reported net income of (40.47 Million). This is 111.86% lower than that of the Biotechnology sector and 157.77% lower than that of the Health Care industry. The net income for all United States stocks is 107.09% higher than that of the company.
Capricor Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Capricor Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Capricor Therapeutics could also be used in its relative valuation, which is a method of valuing Capricor Therapeutics by comparing valuation metrics of similar companies.Capricor Therapeutics is currently under evaluation in net income category among its peers.
Capricor Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Capricor Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Capricor Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Capricor Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Capricor Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Capricor Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Capricor Therapeutics' value.| Shares | Jpmorgan Chase & Co | 2025-06-30 | 195.2 K | Millennium Management Llc | 2025-06-30 | 173.8 K | Oppenheimer & Co Inc | 2025-06-30 | 162.5 K | Two Sigma Investments Llc | 2025-06-30 | 155.8 K | Wellington Management Company Llp | 2025-06-30 | 131.9 K | Barclays Plc | 2025-06-30 | 130.9 K | Hbk Sorce Advisory Llc | 2025-06-30 | 127.6 K | Charles Schwab Investment Management Inc | 2025-06-30 | 120.3 K | Ubs Asset Mgmt Americas Inc | 2025-06-30 | 92.2 K | Blackrock Inc | 2025-06-30 | 3 M | Vanguard Group Inc | 2025-06-30 | 2.3 M |
Capricor Fundamentals
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (7.79) % | ||||
| Current Valuation | 1.2 B | ||||
| Shares Outstanding | 54.4 M | ||||
| Shares Owned By Insiders | 16.79 % | ||||
| Shares Owned By Institutions | 39.24 % | ||||
| Number Of Shares Shorted | 5.11 M | ||||
| Price To Earning | 42.39 X | ||||
| Price To Book | 15.26 X | ||||
| Price To Sales | 105.42 X | ||||
| Revenue | 22.27 M | ||||
| Gross Profit | (64.75 M) | ||||
| EBITDA | (41.14 M) | ||||
| Net Income | (40.47 M) | ||||
| Cash And Equivalents | 51.42 M | ||||
| Cash Per Share | 2.11 X | ||||
| Total Debt | 1.45 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 2.69 X | ||||
| Book Value Per Share | 1.83 X | ||||
| Cash Flow From Operations | (40 M) | ||||
| Short Ratio | 3.91 X | ||||
| Earnings Per Share | (1.75) X | ||||
| Target Price | 50.8 | ||||
| Number Of Employees | 160 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 1.17 B | ||||
| Total Asset | 170.48 M | ||||
| Retained Earnings | (199.83 M) | ||||
| Working Capital | 142.36 M | ||||
| Current Asset | 22.4 M | ||||
| Current Liabilities | 6.67 M | ||||
| Net Asset | 170.48 M |
About Capricor Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Capricor Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Capricor Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Capricor Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Capricor Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Capricor Stock
Moving against Capricor Stock
| 0.8 | SYBX | Synlogic | PairCorr |
| 0.74 | PCSA | Processa Pharmaceuticals | PairCorr |
| 0.61 | LEXX | Lexaria Bioscience Corp | PairCorr |
| 0.61 | BKRKF | PT Bank Rakyat | PairCorr |
| 0.6 | CRIS | Curis Inc | PairCorr |
The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.
The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.